ReviewCells2020
Insight into the Role of Angiopoietins in Ageing-Associated Diseases.
Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 32 citations in OpenAlex.
- "Morphological, Functional, and Molecular Progression of Blood-Brain Barrier Dysfunction in Alzheimer's Disease".Journal of molecular neuroscience : MN · 2026Review
- Refining Vascular Biomarker-Guided Risk Stratification for Cancer Therapy-Related Cardiac Dysfunction.JACC. CardioOncology · 2026Article
- Distinct patterns of endothelial response to endotoxin in aged mice as compared to young mice.GeroScience · 2026Article
- Serum proteomics reveals biomarkers for diagnosis, stratification, and mechanistic insights into cerebral microbleeds.Frontiers in aging neuroscience · 2026Article
- Exploring the molecular mechanisms of comorbidity between thyroid cancer and breast cancer through multi-omics data.Scientific reports · 2025Article
- Is the Relationship Between Cardiovascular Disease and Alzheimer's Disease Genetic? A Scoping Review.Genes · 2024Article
- A single nuclear transcriptomic characterisation of mechanisms responsible for impaired angiogenesis and blood-brain barrier function in Alzheimer's disease.Nature communications · 2024Article
- Phosphodiesterase inhibitor ameliorates senescent changes of renal interstitial pericytes in aging kidney.Aging cell · 2024Article
- Elevated CSF angiopoietin-2 correlates with blood-brain barrier leakiness and markers of neuronal injury in early Alzheimer's disease.Translational psychiatry · 2024Article
- Targeting DNA methylation and demethylation in diabetic foot ulcers.Journal of advanced research · 2023Review
- scDiffCom: a tool for differential analysis of cell-cell interactions provides a mouse atlas of aging changes in intercellular communication.Nature aging · 2023Article
- mPeerJ · 2023Article
- A system pharmacology Boolean network model for the TLR4-mediated inflammatory response in early sepsis.Journal of pharmacokinetics and pharmacodynamics · 2022Article
- The Effect of High and Variable Glucose on the Viability of Endothelial Cells Co-Cultured with Smooth Muscle Cells.International journal of molecular sciences · 2022Article
- Combination of polyglycerol sebacate coated with collagen for vascular engineering.Journal of cardiovascular and thoracic research · 2022Article
- The Potential Role of Cytokines and Growth Factors in the Pathogenesis of Alzheimer's Disease.Cells · 2021Review
- Article
- Inflammatory Mechanisms Contributing to Endothelial Dysfunction.Biomedicines · 2021Review
- Cerebral Amyloid Angiopathy in a Mouse Model of Alzheimer's Disease Associates with Upregulated Angiopoietin and Downregulated Hypoxia-Inducible Factor.Journal of Alzheimer's disease : JAD · 2021Article
- Apelin Promotes Endothelial Progenitor Cell Angiogenesis in Rheumatoid Arthritis DiseaseFrontiers in immunology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Angiopoietin (Ang) and its receptor, TIE signaling, contribute to the development and maturation of embryonic vasculature as well as vascular remodeling and permeability in adult tissues. Targeting both this signaling pathway and the major pathway with vascular endothelial growth factor (VEGF) is expected to permit clinical applications, especially in antiangiogenic therapies against tumors. Several drugs targeting the Ang-TIE signaling pathway in cancer patients are under clinical development. Similar to how cancer increases with age, unsuitable angiogenesis or endothelial dysfunction is often seen in other ageing-associated diseases (AADs) such as atherosclerosis, Alzheimer's disease, type 2 diabetes, chronic kidney disease and cardiovascular diseases. Thus, the Ang-TIE pathway is a possible molecular target for AAD therapy. In this review, we focus on the potential role of the Ang-TIE signaling pathway in AADs, especially non-cancer-related AADs. We also suggest translational insights and future clinical applications of this pathway in those AADs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.